| Title |
Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
|
|---|---|
| Published in |
Cancer Management and Research, July 2017
|
| DOI | 10.2147/cmar.s139305 |
| Pubmed ID | |
| Authors |
Joelle El-Amm, Rami Nassabein, Jeanny B Aragon-Ching |
| Abstract |
Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre-chemotherapy) setting, respectively, with improvement in overall survival as well as secondary end points such as prostate-specific antigen (PSA) and radiographic response rates, time to PSA progression, and progression-free survival. There has been a lot of interest and emphasis in the evaluation of patient-related outcomes (PROs) as it relates to quality of life, pain, adverse events, fatigue, and among others, in the use of different agents that have been shown to improve survival. This review examines the companion PROs in conjunction with abiraterone acetate use. This is particularly relevant since PROs are increasingly viewed as a key metric for drug label claims in granting approval across regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Colombia | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 14% |
| Student > Bachelor | 5 | 14% |
| Professor | 4 | 11% |
| Student > Ph. D. Student | 4 | 11% |
| Other | 3 | 8% |
| Other | 8 | 22% |
| Unknown | 7 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 31% |
| Nursing and Health Professions | 5 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 11% |
| Psychology | 2 | 6% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 4 | 11% |
| Unknown | 9 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 July 2017.
All research outputs
#17,908,059
of 22,994,508 outputs
Outputs from Cancer Management and Research
#946
of 2,014 outputs
Outputs of similar age
#225,303
of 314,055 outputs
Outputs of similar age from Cancer Management and Research
#12
of 15 outputs
Altmetric has tracked 22,994,508 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,014 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,055 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.